Our journey continues to evolve, thanks to constant feedback from our diverse team of experts, who are dedicated to addressing the unmet clinical needs associated with mitochondrial dysfunction
We strive to be a global leader in the development of novel mitochondrial cell therapies to treat people stricken with diseases of mitochondrial dysfunction. Every day, together with the world's leading scientists, clinicians, and patient advocacy groups, we are translating our mitochondrial science into meaningful therapies for multiple disorders associated with mitochondrial dysfunction.
Minovia’s logo contains Starlings in Flight.
Flying together, constantly pivoting without colliding, symbolizing close collaboration with constant communication in a dynamic atmosphere.
Our ability to execute is driven by our highly experienced executive team, comprehensive regulatory strategy and clinical development plan in partnerships with key physicians and advisors.
Co-founder & CEO
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide.
Chief Scientific Officer
Noa is highly experienced research leader in the cell therapy space and a molecular and cellular biologist by training. Noa received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral studies at the Whitehead Institute, MIT, Cambridge, MA and at the Technion Institute of Technology in Israel. She joined Minovia after several years as head of a research team heading preclinical development and characterization of all clinical-stage products at Pluristem, an Israeli-based cell therapy company.
Nadav has more than 10 years of experience in the world of cell therapy, focusing on process development and manufacturing.
He is an expert in developing complex cell therapy processes, optimization, scale-up, tech transfer from development to manufacturing, and process implementation in the manufacturing line, both in start-ups, and in large manufacturing companies.
Before joining Minovia, Nadav led the departments of development and manufacturing at Pluristem, an Israeli-based cell therapy company.
VP People and Culture
Limor is an experienced senior HR leader with over 18 years of experience in health-tech companies. She has deep professional knowledge of the biotech field, and personal experience as a manager. Before joining Minovia, Ms. Lior worked at Pluristem Therapeutics in various multi-disciplinary roles, including Manufacturing Manager and Organizational Development Senior Manager, and HRBP. She holds an MSc. in Biotechnology Engineer from the Technion, and she’s a certified coach, mediator and group facilitator. Limor is dedicated to the organization’s people, culture, and their continued development, and has a passion for innovative technologies that impact human life.
Chairman of the Board
John joined Minovia Therapeutics in February 2019 and brings over 25 years of experience in biopharmaceuticals. Mr. Cox is currently the Chief Executive Officer of Repertoire Immune Medicines, and was formerly the CEO of Bioverativ, which he built and grew from a new venture with two drugs, Eloctate® and Alprolix® for the treatment of hemophilia A and B. In February 2018 Mr. Cox led Bioverativ to a successful acquisition by Sanofi for $11.6B.
Maha joined Minovia Therapeutics bringing significant experience across a broad range of therapeutic areas and disciplines, including CNS (neurology and psychiatry), rheumatology and immunology, rare blood disorders, ophthalmology, cardiology, diabetes, and internal medicine. Maha is currently CMO of Biogen, and formerly held senior medical roles in Sanofi, Bioverativ, BMS, Cephalon, and United Health Group before joining Biogen in 2013.
Ilan is an experienced biotech executive.
He is the former President and CEO of Solid Biosciences, a company he co-founded to develop treatments for Duchenne muscular dystrophy. Prior to starting Solid, Ilan spent a decade as an investment banker at JPMorgan, Nomura and Lehman Brothers in London, Hong Kong and New York. Earlier in his career Ilan practiced law at the Israeli law-firm, Haim Zadok & Co.
Co-founder, CEO & Board Member
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with passion to help children ans adults with mitochondrial diseases worldwide.
Co-founder & Board Member
Ephraim is an Ex-Deputy Head, Israel Institute for Biological Research. He is a former executive at Siemens Israel and a serial angel investor in Israeli start-up companies.